{
    "data": [
        {
            "title": "Global Real-time PCR Systems Market to Reach USD 13.7 Billion by 2035, with Canada Being Top Performing Country at a Decent 8.9% Value CAGR from 2025 to 2035 | Future Market Insights, Inc.",
            "description": "<div class=\"mdc-article-body\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">The real-time PCR systems industry is expanding, led by the U.S. in North America, with Germany driving growth in Europe. Asia-Pacific, especially Japan and China, is rising fast due to biotech investments. Advances in PCR tech and disease surveillance boost demand.</strong></em></p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">NEWARK, DE / <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.accessnewswire.com/\" tabindex=\"0\">ACCESS Newswire</a> / February 4, 2025 / </strong>According to a Future Market Insights (FMI), the global <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rwn\" tabindex=\"0\">real-time PCR systems market</a> is projected to grow from <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">USD 6.3 Billion</strong> in 2025 to <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">USD 13.7 Billion</strong> by 2035, registering a <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">CAGR of 8%</strong> during the forecast period. Increasing adoption of molecular diagnostic techniques, advancements in PCR technology, and rising applications in infectious disease detection and oncology are key growth drivers. North America and Europe remain dominant regions, while Asia-Pacific is witnessing rapid expansion due to growing healthcare infrastructure investments.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Get Your Sample Report Now - Gain Exclusive Market Insights!</strong><br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rwo\" tabindex=\"0\">https://www.futuremarketinsights.com/report-sample#5245502d47422d38333936</a></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Market Overview:</strong></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Real-time PCR (polymerase chain reaction) systems are critical tools in molecular diagnostics, enabling precise quantification of nucleic acids. These systems have gained widespread use in <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rwp\" tabindex=\"0\">clinical diagnostics</a>, pharmaceutical research, and forensic testing due to their accuracy, speed, and automation capabilities. With increasing applications in disease diagnosis, pathogen detection, and genetic analysis, the demand for real-time PCR systems is growing rapidly.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Market Forecast: 2025 to 2035</strong></p><ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Market Size 2025:</strong> USD 6.3 Billion</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Projected Market Size 2035:</strong> USD 13.7 Billion</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">CAGR (2025-2035):</strong> 8%</p></li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The rising prevalence of infectious diseases, including emerging viral outbreaks, is a major factor fueling market growth. Additionally, increasing investments in precision medicine and personalized therapies are boosting the adoption of real-time PCR systems.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Key Growth Drivers:</strong></p><ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Advancements in PCR Technology:</strong> Continuous innovations such as multiplex PCR, digital PCR, and microfluidic-based PCR systems are enhancing the efficiency and accuracy of molecular testing.</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Rising Demand for Rapid and Accurate Diagnostics:</strong> Real-time PCR plays a crucial role in identifying infectious agents, genetic disorders, and cancer biomarkers, driving its widespread adoption.</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Expanding Applications in Research and Clinical Fields:</strong> Increasing use in oncology, reproductive health, forensic science, and <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rwq\" tabindex=\"0\">veterinary diagnostics</a> is contributing to market growth.</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Government Initiatives for Disease Surveillance:</strong> Public health agencies worldwide are investing in molecular diagnostic capabilities to detect and control infectious disease outbreaks efficiently.</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Integration with AI and Automation:</strong> The incorporation of artificial intelligence and automated workflows in PCR systems is improving diagnostic accuracy and reducing turnaround times.</p></li></ul><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://app.accessnewswire.com/imagelibrary/e3258125-8c3b-4033-81fd-ed4cbb1638b0/979200/real-time-pcr-systems-market.png 1x,https://app.accessnewswire.com/imagelibrary/e3258125-8c3b-4033-81fd-ed4cbb1638b0/979200/real-time-pcr-systems-market.png 2x,https://app.accessnewswire.com/imagelibrary/e3258125-8c3b-4033-81fd-ed4cbb1638b0/979200/real-time-pcr-systems-market.png 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://app.accessnewswire.com/imagelibrary/e3258125-8c3b-4033-81fd-ed4cbb1638b0/979200/real-time-pcr-systems-market.png 1x,https://app.accessnewswire.com/imagelibrary/e3258125-8c3b-4033-81fd-ed4cbb1638b0/979200/real-time-pcr-systems-market.png 2x,https://app.accessnewswire.com/imagelibrary/e3258125-8c3b-4033-81fd-ed4cbb1638b0/979200/real-time-pcr-systems-market.png 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://app.accessnewswire.com/imagelibrary/e3258125-8c3b-4033-81fd-ed4cbb1638b0/979200/real-time-pcr-systems-market.png 1x,https://app.accessnewswire.com/imagelibrary/e3258125-8c3b-4033-81fd-ed4cbb1638b0/979200/real-time-pcr-systems-market.png 2x,https://app.accessnewswire.com/imagelibrary/e3258125-8c3b-4033-81fd-ed4cbb1638b0/979200/real-time-pcr-systems-market.png 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://app.accessnewswire.com/imagelibrary/e3258125-8c3b-4033-81fd-ed4cbb1638b0/979200/real-time-pcr-systems-market.png\"/></source></source></source></picture></span><span> </span><span> </span><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Latest Trends Shaping the Global Market:</strong></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Development of Portable and Point-of-Care PCR Devices:</strong> The rise of compact, handheld real-time PCR devices is enhancing accessibility in remote and resource-limited settings.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Growing Adoption of Digital PCR (dPCR):</strong> Digital PCR is gaining traction for its higher sensitivity and absolute quantification capabilities, particularly in oncology and infectious disease testing.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Expansion in Food Safety and Environmental Testing:</strong> PCR-based pathogen detection in food products and environmental monitoring is becoming more prevalent.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Strategic Collaborations and Mergers:</strong> Key players are engaging in partnerships to enhance technological capabilities and expand their global footprint.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Explore Report Details for In-Depth Insights about Trends &amp; Drivers!</strong><br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rwr\" tabindex=\"0\">https://www.futuremarketinsights.com/reports/real-time-pcr-systems-market</a></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Key Takeaways from the Report:</strong></p><ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The global real-time PCR systems market will grow at an <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">8% CAGR</strong> from 2025 to 2035.</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The market will be worth <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">USD 13.7 Billion</strong> by 2035.</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Increasing demand for precision medicine, rapid diagnostics, and genetic research is accelerating market expansion.</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">North America and Europe will continue to dominate the market, while Asia-Pacific is expected to witness the highest growth.</p></li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">\"The growing emphasis on molecular diagnostics, particularly in infectious disease management and oncology, is a major driver for real-time PCR system adoption. The integration of AI-driven automation and digital PCR technology will further enhance diagnostic accuracy and efficiency, paving the way for rapid market expansion.\"</strong></em> - opines <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rws\" tabindex=\"0\">Nikhil Kaitwade</a>, Associate Vice President at Future Market Insights (FMI).</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Regional Outlook:</strong></p><ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">United States:</strong> Expected to grow at a <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">7.1% CAGR</strong>, driven by robust healthcare infrastructure, extensive R&amp;D initiatives, and strong government support for infectious disease surveillance.</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Canada:</strong> Anticipated to register an <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">8.9% CAGR</strong> due to rising investments in biotechnology and genomic research.</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Germany:</strong> Forecasted to grow at an <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">8.7% CAGR</strong>, supported by advancements in molecular diagnostics and increasing healthcare expenditures.</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">China:</strong> Projected to expand at a <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">7.6% CAGR</strong>, fueled by a growing biotechnology sector and expanding diagnostic capabilities.</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Japan:</strong> Expected to witness an <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">8.2% CAGR</strong>, driven by innovations in precision medicine and early disease detection initiatives.</p></li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Access In-Depth Analysis - Request Your Sample Copy Now!</strong><br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rwt\" tabindex=\"0\">https://www.futuremarketinsights.com/report-sample#5245502d47422d38333936</a></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Leading Companies Operating in the Market:</strong></p><ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Thermo Fisher Scientific</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Agilent Technologies</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Abbot Laboratories</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Danaher Corporation</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Bio-Rad Laboratories Inc.</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">QIAGEN</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">GE Healthcare</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Merck KGaA</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Hoffmann-La Roche AG</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Fluidigm Corporation.</p></li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Real-time PCR Systems Industry Segmentation Analysis:</strong></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">By Product Type:</strong></p><ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Real-time PCR instruments</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Real-time PCR consumables and reagents</p></li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">By Application:</strong></p><ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Blood and oncology testing</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Pathogen testing</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Research &amp; development</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Forensic science</p></li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">By End Use:</strong></p><ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Clinical research organizations</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Research laboratories</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Educational institutes</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Diagnostic centres</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Hospitals</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Other end users</p></li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">By Region:</strong></p><ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">North America</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Latin America</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Western Europe</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Eastern Europe</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">East Asia</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">South Asia Pacific</p></li><li data-v-6f730619=\"\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Middle East &amp; Africa</p></li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Explore Future Market Insights, Inc. Extensive Coverage in </strong><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rwu\" tabindex=\"0\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Testing Equipment</strong></a><strong class=\"mdc-article-strong\" data-v-43363f62=\"\"> Domain:</strong></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The global <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rwv\" tabindex=\"0\">laboratory benchtop automation market value</a> forecasted to exceed USD 2,470.2 Million by 2035.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The global <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rww\" tabindex=\"0\">microplate instrumentation and supplies market revenue</a> projected to cross USD 9.8 Billion by 2033.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The global <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rwx\" tabindex=\"0\">laboratory furnaces market share</a> anticipated to surpass USD 632.1 Million mark by 2035.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The global <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rwy\" tabindex=\"0\">electrophoresis equipment and supplies market size</a> anticipated to reach USD 3.4 Billion by 2033.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The global <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rwz\" tabindex=\"0\">dosage unit sampling apparatus industry</a> expected to surpass USD 6 Billion value by 2032.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The global <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rx0\" tabindex=\"0\">laboratory filtration equipment and supplies demand</a> predicted to surge at 7% CAGR through 2032.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The global <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rx1\" tabindex=\"0\">orbital shakers market revenue share</a> anticipated to surge at 6.6% CAGR from 2018-2027.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The global <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rx2\" tabindex=\"0\">specific gravity bench apparatus market valuation</a> is forecasted to reach USD 85.86 Million by 2032.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The global <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rx3\" tabindex=\"0\">laboratory ovens market</a> is expected to rise steadily at 4.4% CAGR from 2018 to 2027.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The global <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rx4\" tabindex=\"0\">sales of battery testing equipment</a> to reach USD 868.7 Million milestone by the end of 2035.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About Future Market Insights (FMI):</strong></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI's latest market research reports and market analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Contact Us:</strong></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Future Market Insights Inc.<br data-v-02ca9be7=\"\"/>Christiana Corporate, 200 Continental Drive,<br data-v-02ca9be7=\"\"/>Suite 401, Newark, Delaware - 19713, USA<br data-v-02ca9be7=\"\"/>T: +1-347-918-3531<br data-v-02ca9be7=\"\"/><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">For Sales Enquiries: </strong><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:sales@futuremarketinsights.com\" tabindex=\"0\">sales@futuremarketinsights.com</a><br data-v-02ca9be7=\"\"/><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Website:</strong><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rx5\" tabindex=\"0\">https://www.futuremarketinsights.com</a><br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rx6\" tabindex=\"0\">LinkedIn</a> | <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rx7\" tabindex=\"0\">Twitter</a> | <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rx8\" tabindex=\"0\">Blogs</a> | <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://pr.report/6rx9\" tabindex=\"0\">YouTube</a></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">SOURCE: </strong>Future Market Insights, Inc.</p><br/><br/>View the original <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/global-real-time-pcr-systems-market-to-reach-usd-137-billion-by-20-979200\" tabindex=\"0\">press release</a> on ACCESS Newswire<br/><br/>\n<span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://app.accessnewswire.com/img.ashx?id=979200 1x,https://app.accessnewswire.com/img.ashx?id=979200 2x,https://app.accessnewswire.com/img.ashx?id=979200 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://app.accessnewswire.com/img.ashx?id=979200 1x,https://app.accessnewswire.com/img.ashx?id=979200 2x,https://app.accessnewswire.com/img.ashx?id=979200 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://app.accessnewswire.com/img.ashx?id=979200 1x,https://app.accessnewswire.com/img.ashx?id=979200 2x,https://app.accessnewswire.com/img.ashx?id=979200 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://app.accessnewswire.com/img.ashx?id=979200\"/></source></source></source></picture></span></div>",
            "pub_date": "2025-02-04 17:45:48",
            "link": "https://www.morningstar.com/news/accesswire/979200msn/global-real-time-pcr-systems-market-to-reach-usd-137-billion-by-2035-with-canada-being-top-performing-country-at-a-decent-89-value-cagr-from-2025-to-2035-future-market-insights-inc",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Valerio Therapeutics Announces Strategic Refocus",
            "description": "<div class=\"mdc-article-body\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">Valerio Therapeutics Announces Strategic Refocus</em></strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nRegulatory News:\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nValerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) today announced a strategic decision to discontinue all clinical trials and associated activities, including the ongoing VIO-01 trial. This shift was decided by the board of directors in the context of the financing challenges of the Company. The Company’s cash position should enable it to finance its refocused business other the next three months. In the meantime, in addition to the reduction of its expenses, it is negotiating with its stakeholders and is seeking to reach the agreement needed to secure its financial and cash trajectory in the next twelve months.\n<br data-v-02ca9be7=\"\"/>The end of clinical trials will enable the company to focus exclusively on early-stage drug development, ensuring efficient use of available capital while maintaining a strong focus on innovation.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nAs part of this transition, Valerio will cease clinical-stage operations in oncology and close its U.S. office in Lexington, MA. The company is conducting a strategic review to redefine its pipeline and long-term vision, ensuring sustainable growth and value creation for stakeholders. The Company will focus on its early-stage activities, namely the development of its single chain antibody platform, which, coupled with chemistry capabilities and oligonucleotides expertise, can open new avenues for the company.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nThe company will update the market as soon as the ongoing discussions with its stakeholders lead to securing a long-term financing solution to achieve its strategic development milestones.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">Julien Miara, Chairperson and CEO of Valerio Therapeutics, commented:\n<br data-v-370fea16=\"\"/></em></strong><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">“This decision, which will help consolidate the financial position of the company together with other actions, allows us to focus on our core strengths in early-stage research while preserving financial flexibility to drive transformative innovation. We extend our gratitude to the patients, investigators, and partners who have supported our clinical efforts and remain steadfast in our mission to develop novel therapies addressing critical unmet needs.\n<br data-v-370fea16=\"\"/></em><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">Valerio is committed to providing updates on its revised strategy and future plans in due course.</em><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">”</em>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nFor more information, visit <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fus-west-2.protection.sophos.com%2F%3Fd%3Desvalabs.com%26u%3DaHR0cHM6Ly91cmxzYW5kLmVzdmFsYWJzLmNvbS8_dT1odHRwJTNBJTJGJTJGd3d3LnZhbGVyaW90eC5jb20mZT0yYjIyYzlhMCZoPTUyY2MwZDA2JmY9biZwPXk%3D%26p%3Dm%26i%3DNjczNzJjZjcyOGFhYTk1OWU0YjY5NDRk%26t%3DbGpTUlFBMDgyenU4MDJNVW42aFdVM0QxZ0gxMjJhVG4vWXBvN2c2QW5ldz0%3D%26h%3D7ea3a191c97e430b8360688c82aae09a%26s%3DAVNPUEhUT0NFTkNSWVBUSVbHJ93uCmwCLkhjuvIiJAjmrT6rvdO4ZkuE-S527ip4wLcyeWyrpBtnYjD90igWU90&amp;esheet=54199052&amp;newsitemid=20250204093872&amp;lan=en-US&amp;anchor=www.valeriotx.com&amp;index=1&amp;md5=656b2efdce7efebfb7784d9cb8d16cbc\" tabindex=\"0\">www.valeriotx.com</a>.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">Forward looking statements\n<br data-v-370fea16=\"\"/></em></strong>This communication expressly or implicitly contains certain forward-looking statements concerning Valerio Therapeutics and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Valerio Therapeutics to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Valerio Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risk and uncertainties which could cause actual results, financial condition, performance or achievements of Valerio Therapeutics to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent company’s annual financial report or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fvaleriotx.com%2F&amp;esheet=54199052&amp;newsitemid=20250204093872&amp;lan=en-US&amp;anchor=www.valeriotx.com&amp;index=2&amp;md5=f88bf6fd05a7e139975861050ff2105a\" tabindex=\"0\">www.valeriotx.com</a>) and/or the AMF (<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org%2F&amp;esheet=54199052&amp;newsitemid=20250204093872&amp;lan=en-US&amp;anchor=www.amf-france.org&amp;index=3&amp;md5=e399bc078b76c4ec5086c5130cebcf52\" tabindex=\"0\">www.amf-france.org</a>)\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250204093872r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 1x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250204093872r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 2x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250204093872r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250204093872r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 1x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250204093872r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 2x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250204093872r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250204093872r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 1x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250204093872r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 2x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250204093872r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250204093872r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en\"/></source></source></source></picture></span><span data-v-02ca9be7=\"\"></span></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Valerio Therapeutics \n</strong><br data-v-02ca9be7=\"\"/>Investor Relations\n<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:ir@valeriotx.com\" tabindex=\"0\">ir@valeriotx.com</a> | +33 (0) 1 70 38 33 99\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">View source version on businesswire.com: </span><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.businesswire.com/news/home/20250204093872/en/\" tabindex=\"0\">https://www.businesswire.com/news/home/20250204093872/en/</a></span></p></div>",
            "pub_date": "2025-02-04 17:45:47",
            "link": "https://www.morningstar.com/news/business-wire/20250204093872/valerio-therapeutics-announces-strategic-refocus",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "UBS Aims to Boost Buybacks as Net Profit Beats Expectations — 2nd Update",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  By Adria Calatayud </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  UBS Group aims to buy back up to $3 billion in its own stock this year as it reported a better-than-expected net profit for the fourth quarter thanks to its investment bank and cost controls. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The Zurich-based group resumed share repurchases last year after a pause due to its takeover of Credit Suisse in 2023. The bank is seeking to bolster its returns to shareholders so that its buybacks next year exceed the levels of 2022, before the rescue deal for its former cross-town rival. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  UBS reiterated that ambition on Tuesday, with the caveat that its plans remain subject to maintaining a capital ratio above its target, achieving financial goals and the absence of immediate changes to current capital rules in Switzerland. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The prospect of tougher regulations that are expected to increase the bank's capital demands in its home country has cast a cloud on its plans to return more money to shareholders. Analysts have said the new requirements could make UBS alter its plans. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  UBS said it plans to repurchase $1 billion of its own stock in the first half and aims to buy back up to an additional $2 billion in the second half. It also hiked its dividend by 29% to $0.90 a share. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The dividend increase should give the market confidence that UBS can resolve its capital issues organically while maintaining buybacks, analysts at JPMorgan wrote in a note to clients. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The update sent UBS's shares up as much as 3% in early morning trade in Europe, but the stock fell later. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  UBS's fourth-quarter results once again reflected its efforts to integrate Credit Suisse after the takeover engineered by Swiss authorities. Lower integration-expense bills and stronger-than-expected results at its investment bank lifted earnings. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The Swiss banking group said net profit for the quarter was $770 million compared with a loss of $279 million in the year-earlier period, when its results were hit by costs related to the integration of Credit Suisse. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Analysts had expected a net profit of $483 million, according to consensus estimates compiled by the bank. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Revenue for the quarter came in at $11.635 billion, up from $10.855 billion a year before. Analysts had expected $11.51 billion, according to the same consensus. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  UBS's core global wealth management arm brought in $18 billion in net new assets last quarter, a slowdown from $25 billion in the prior quarter. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  \"We are confident in our ability to substantially complete the integration by the end of 2026, achieve our financial targets, and fulfill our growth initiatives as we position UBS for a successful future,\" Chief Executive Sergio Ermotti said. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  UBS said it expects gross cost savings from the integration of around $2.5 billion in 2025 and that it is on track to deliver about $13 billion in savings by the end of next year. However, the bank now anticipates cumulative expenses of around $14 billion, higher than previously assumed. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The bank said constructive market conditions have continued into the first quarter of 2025 after investors ended 2024 on a positive note, but cautioned that increased uncertainties around global trade, inflation and central bank policies might trigger volatility. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Write to Adria Calatayud at adria.calatayud@wsj.com </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  February 04, 2025 04:26 ET (09:26 GMT)</p>\n\nCopyright (c) 2025 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2025-02-04 17:40:41",
            "link": "https://www.morningstar.com/news/dow-jones/202502042509/ubs-aims-to-boost-buybacks-as-net-profit-beats-expectations-2nd-update",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Grab Mulls Takeover of GoTo at $7 Billion Valuation, Bloomberg Says, Citing Sources",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  --Grab Holdings is weighing a takeover of rival GoTo Group at a valuation of more than $7 billion, Bloomberg reported Tuesday, citing unnamed sources. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  --The companies have held on-and-off talks for years, Bloomberg said. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  --Discussions have intensified in recent weeks and the companies see this year as an opportune time for a deal, the people said, according to Bloomberg. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  --A GoTo spokesperson declined to comment, while Grab had no immediate comment, the Bloomberg report said. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Full story: https://www.bloomberg.com/news/articles/2025-02-04/grab-goto-accelerate-merger-talks-and-aim-for-deal-in-2025 </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Write to Kimberley Kao at kimberley.kao@wsj.com </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  February 04, 2025 04:10 ET (09:10 GMT)</p>\n\nCopyright (c) 2025 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2025-02-04 17:25:45",
            "link": "https://www.morningstar.com/news/dow-jones/202502042401/grab-mulls-takeover-of-goto-at-7-billion-valuation-bloomberg-says-citing-sources",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "News Highlights: Top Energy News of the Day - Tuesday at 4 AM ET",
            "description": "<div class=\"mdc-article-body\">\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\">OMV's Net Profit Rises Despite Weak Refining Margins \n </pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The oil-and-gas company's refining margin fell to $5.9 a barrel, compared with $9.9 a barrel a year ago. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"> \nOil Rises as Trump's Tariffs Raise Supply Fears \n </pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Prices jumped on concerns that U.S. tariffs against its major trade partners could disrupt supplies and raise prices at the pump. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"> \nExxon Enters the Electricity Business, Takes a Swipe at Nuclear \n </pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Exxon says it can compete with nuclear, because the gas power plants it intends to build would capture carbon emissions. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"> \nU.S. Frackers and Saudi Officials Tell Trump They Won't Drill More \n </pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The president says lower prices could solve a range of problems, but finds early resistance in the oil market. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"> \nExxon, Chevron Yearly Profits Down as Investor Payouts Hit Fresh Highs \n </pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Annual profits fell, but the oil giants made record distributions to shareholders as production rose to historic levels in key regions. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"> \nEnergy &amp; Utilities Roundup: Market Talk \n </pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Read about tariffs on Canadian oil, natural gas prices, Galp Energia and more in the latest Market Talks covering Energy and Utilities. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"> \nOrsted Replaces CEO as Wind Industry Faces Challenges \n </pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The company said it is parting ways with Mads Nipper as it grapples with supply-chain bottlenecks, high financing costs and President Trump's opposition to wind power. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"> \nTariffs Won't Sink Canadian Oil Companies \n </pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The U.S. has become reliant on their crude, and Canada has ways to limit any financial hit. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"> \nShell Keeps $3.5 Billion Buyback Amid Earnings Miss \n </pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The oil-and-gas company's adjusted earnings fell more than expected, weighed by lower oil prices and refining margins. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"> \nU.S. Crude Oil Stockpiles Rise for First Time in 10 Weeks \n </pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  U.S. crude oil inventories increased for the first time in 10 weeks, beating analyst's expectations, as exports fell and refineries lowered their capacity use. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"> \n </pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  February 04, 2025 04:15 ET (09:15 GMT)</p>\n\nCopyright (c) 2025 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2025-02-04 17:25:44",
            "link": "https://www.morningstar.com/news/dow-jones/202502042430/news-highlights-top-energy-news-of-the-day-tuesday-at-4-am-et",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "ScienceMedia® Set to Launch SMi Engage™ at 2025 SCOPE Summit",
            "description": "<div class=\"mdc-article-body\">\n\n\n\n\n\nScienceMedia® Set to Launch SMi Engage™ at 2025 SCOPE Summit\n\n\n\n\n\n<span>\n<h2 class=\"mdc-article-heading\" data-v-2dc4c42a=\"\">ScienceMedia® Set to Launch SMi Engage™ at 2025 SCOPE Summit</h2>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SAN DIEGO, Feb. 4, 2025</p></span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Patient-centric video training solution builds trust and simplifies clinical trial enrollment, engagement, and retention</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">SAN DIEGO</span></span>, <span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Feb. 4, 2025</span></span> /PRNewswire/ -- <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://sciencemedia.com/\" tabindex=\"0\">ScienceMedia<span data-v-4234e9e2=\"\">®</span></a>, a leader in life science clinical training solutions, is pleased to announce the launch of <span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://sciencemedia.com/engage\" tabindex=\"0\">SMi Engage</a></span><span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://sciencemedia.com/engage\" tabindex=\"0\">™</a></span>, a customized, video-based training solution that aids enrollment, minimizes dropout, and increases active engagement among clinical trial participants. Launching at the SCOPE Summit 2025 in <span data-v-02ca9be7=\"\">Florida</span> this February, SMi Engage is set to transform clinical trial participation by providing accessible education that educates, builds trust, and encourages active involvement of study participants.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SMi Engage addresses a critical need among sites, sponsors, and CROs, offering engaging, bite-sized content that explains study expectations clearly. With concise video summaries of the trial procedures and consent documents, this new product empowers study participants to make informed decisions to enroll faster and feel supported throughout the trial.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\"SMi Engage™ represents a major step forward in empowering clinical trial participants and overcoming longstanding barriers to diversity and inclusion,\" said <span data-v-02ca9be7=\"\">Malachi Bierstein</span>, Chief Commercial Officer of ScienceMedia<span data-v-02ca9be7=\"\">®</span>. \"By providing accessible, easy-to-understand training, SMi Engage drives informed consent and helps participants feel empowered throughout the trial, ultimately improving outcomes for sponsors, sites, and patients alike.\"</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">SMi Engage:</strong></p>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Speeds enrollment</strong> with engaging, video-based training</li><li data-v-6f730619=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Simplifies informed consent</strong> with accessible, easy-to-understand content</li><li data-v-6f730619=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Strengthens retention</strong> with content that engages and builds trust</li><li data-v-6f730619=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Supports representative populations</strong> through patient-focused education</li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">To see the solution live, <span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://calendly.com/pbedrin\" tabindex=\"0\">book a demo</a></span> in booth 1312 with the ScienceMedia team at SCOPE Summit, <span data-v-02ca9be7=\"\">February 3-6, 2025</span>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About ScienceMedia<span data-v-43363f62=\"\">®</span></strong><br data-v-02ca9be7=\"\"/>At the vanguard of clinical trial efficiency and training innovation, <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://sciencemedia.com/\" tabindex=\"0\">ScienceMedia</a> is revolutionizing the industry by shortening trial timelines by up to 20%, accelerating site activations and enrollment, and saving millions in R&amp;D spend per trial. Our <span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://sciencemedia.com/source\" tabindex=\"0\">SMi Source™</a></span>, <span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://sciencemedia.com/trial\" tabindex=\"0\">SMi Trial™</a></span>, and <span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://sciencemedia.com/engage\" tabindex=\"0\">SMi Engage™</a></span> solutions are transforming therapeutic area training, clinical study operations, and clinical trial participation for biopharma, medtech, and CROs, Learn more at <span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"http://www.sciencemedia.com/\" tabindex=\"0\">www.sciencemedia.com</a></span>. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Media Contact:<br data-v-43363f62=\"\"/></strong><span data-v-02ca9be7=\"\">Claire Dennis</span><br data-v-02ca9be7=\"\"/>Marketing Coordinator<br data-v-02ca9be7=\"\"/>ScienceMedia, Inc.<br data-v-02ca9be7=\"\"/>619-339-0065<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:support@sciencemedia.com\" tabindex=\"0\">support@sciencemedia.com</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=LA10943&amp;sd=2025-02-04 1x,https://c212.net/c/img/favicon.png?sn=LA10943&amp;sd=2025-02-04 2x,https://c212.net/c/img/favicon.png?sn=LA10943&amp;sd=2025-02-04 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=LA10943&amp;sd=2025-02-04 1x,https://c212.net/c/img/favicon.png?sn=LA10943&amp;sd=2025-02-04 2x,https://c212.net/c/img/favicon.png?sn=LA10943&amp;sd=2025-02-04 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=LA10943&amp;sd=2025-02-04 1x,https://c212.net/c/img/favicon.png?sn=LA10943&amp;sd=2025-02-04 2x,https://c212.net/c/img/favicon.png?sn=LA10943&amp;sd=2025-02-04 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://c212.net/c/img/favicon.png?sn=LA10943&amp;sd=2025-02-04\"/></source></source></source></picture></span> View original content:<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.prnewswire.com/news-releases/sciencemedia-set-to-launch-smi-engage-at-2025-scope-summit-302367207.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/sciencemedia-set-to-launch-smi-engage-at-2025-scope-summit-302367207.html</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SOURCE  ScienceMedia</p>\n</span>\n</div>",
            "pub_date": "2025-02-04 17:10:54",
            "link": "https://www.morningstar.com/news/pr-newswire/20250204la10943/sciencemedia-set-to-launch-smi-engage-at-2025-scope-summit",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Percona Announces Comprehensive, Enterprise-Grade Support for Open Source Redis Alternative, Valkey",
            "description": "<div class=\"mdc-article-body\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">RALEIGH, N.C., Feb.  04, 2025  (GLOBE NEWSWIRE) -- <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.globenewswire.com/Tracker?data=xzNBLr4DicqciLk1vrbKEjAOXCTQv4Pp6Hfntqek2BxaQH8rGBf_AX8H0a9tQbIVrayE1_2o_Y-jMfa55NcbPA==\" tabindex=\"0\"><span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\">Percona</span></a>, a global leader in enterprise-grade open source database software and services, today announced the availability of <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.globenewswire.com/Tracker?data=xzNBLr4DicqciLk1vrbKEhxPs94IHc3_zOTL0aXYqjtnpvr4D70zHNBX7jrwW1IZ6RI1kvNtaw07u7d42RScoh7rVF636Zu0AuFdGfraXlsh9HsUv8oEStf7YhB9atvPEPNKA3oEyNdVUIO20FWw1w==\" tabindex=\"0\"><span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\">Percona Support for Valkey</span></a>—a comprehensive, responsive, and flexible service offering that promises to maintain reliable, optimized Valkey deployments whether on-premises, hybrid, or in the</p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">cloud. For organizations not yet using the database management system, Percona has also introduced comprehensive <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.globenewswire.com/Tracker?data=-upcPp_E96Z1adgNS_yuu17W3yrhi6LnuAFdV7O-e7mcWGa7OBcnXVpwGbi23tBUsjPh_8BnR86IVMPK9rACL_FhV3RH1xwDqdhQYM6OH7cStQfoKrvSXYe6jL4VL7YA\" tabindex=\"0\"><span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\">Valkey Migration</span></a> services, to help make the switch from Redis OSS to Valkey as seamless, secure, and non-disruptive as possible.</p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\"When the Linux Foundation first announced its plans for Valkey last March, Percona immediately threw its support behind the project,” said Ann Schlemmer, CEO of Percona. “Beyond the simple fact that many of our customers also relied on Redis for their data operations, we at Percona were motivated by our fundamental belief in the principles of open source—that an open world is a better world—and we remain committed to doing everything we can to help foster and promote such a world.”</p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Valkey: The Open Source Response to Redis’s Controversial Relicensing Decision</strong></p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Announced by The Linux Foundation in March of 2024, Valkey is an open source fork of the popular Redis in-memory, NoSQL key-value datastore. The project was launched in response to Redis’s decision to abandon its long-held commitment to open source licensing in favor of a much more restrictive, source-available model. Today, Redis is now dual-licensed under the Redis Source Available License (RSALv2) and Server Side Public License (SSPLv1), while Valkey has maintained the datastore’s original open source BSD license.</p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">In the wake of these decisions, Valkey has enjoyed an outpouring of support from both the open source and business communities alike. Since its very first announcement, a number of major tech industry players—including Amazon Web Services (AWS), Google Cloud, Ericsson, and Percona—have put their support behind Valkey in a variety of ways. In addition to its commercial support offerings, Percona has dedicated staff to building new capabilities around programmability and security, as well as fixing bugs, on core Valkey projects.</p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Thanks in no small part to such support, Valkey has already established itself as far more than a mere maintenance fork. In the five months between its first formal release (Valkey 7.2.5) in April 2024 and its most recent (Valkey 8.0.0) in September, Valkey has seen major improvements in performance, reliability and efficiency—proving itself to be a dynamic, innovative open source project on course to remain competitive with Redis and other popular in-memory datastores.</p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">As a result, Valkey is already enjoying significant levels of interest and adoption. In a <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.globenewswire.com/Tracker?data=DY3Lby8NK9gM2BTPXJuZFGXTZUfr0ViQsojhDYF7gsXG8hfLR8c5RTcM9YVZjRyMYwJ94zCh2EmQF4rY1DUm3bG4UAbKiiLDsQHbEZij9Rr2XrjwJJ05TWH9icnDnRC4G_wqiPeUmZk2tqLcoMy60w==\" tabindex=\"0\"><span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\">survey report</span></a> from Percona, 75% of Redis users said they were either actively testing, considering or had already adopted Valkey. The study also found that more than three-quarters (76%) of organizations plan to rely on third-party enterprise support for their Valkey deployments.</p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Percona Support for Valkey: Enterprise-Grade Services Tailored to Your Business</strong></p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Percona Support for Valkey boasts several key benefits designed to maintain optimal performance with minimal headaches:</p> <ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Real-Time Expertise:</strong> 24x7x365 responsive support from Valkey specialists.</li><li data-v-6f730619=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Industry-Best SLAs</strong>: Reliable and transparent response times for incidents of every severity level.</li><li data-v-6f730619=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Open Source Commitment:</strong> Freedom from vendor lock-in with full support for Valkey.</li><li data-v-6f730619=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Customizable Solutions</strong>: Tailored plans to fit your unique business needs</li><li data-v-6f730619=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Continuous Development: </strong>Percona experts continue to build out new capabilities around programmability and security,<br data-v-6f730619=\"\"/></li></ul> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Percona Support for Valkey is offered in two core tiers or packages—Advanced, for production environments and Premium, for mission-critical environments. Both offerings help mitigate and resolve some of the most common issues that negatively impact Valkey performance, including inefficient key-value store configurations; high-latency operations and response times; complex Redis-to-Valkey migrations; and misconfigured or under-optimized settings.</p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">In addition to the aforementioned Valkey Migration services, Percona has also introduced the all new <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.globenewswire.com/Tracker?data=huv6qZ_8K4anl2lGly5lg47fiy0Ami1BmqhguFHT-sc2YbxyCXYadvO1THge8cz1pRkN0XtVMA1f2ik6foszlQG6IgQKAz2JnO4jJo2ITE0Soy-50I0E9y_hhX0m6RdU5ZJIHGOKxuv574IBI8EWJw_BM7C09MmDovCfaBgOB2g=\" tabindex=\"0\"><span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\">Redis OSS Health Assessment</span></a>—an in-depth, preemptive evaluation of an organization’s existing Redis deployment(s) and overall migration readiness. Together with its core migration services, Percona helps organizations avoid licensing limitations while optimizing database performance and minimizing downtime; for a reliable, highly-performant open source database solution.</p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Valkey-Interested Organizations Needn’t Venture Alone Any Longer</strong></p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">“The almost immediate explosion of interest and support for Valkey goes beyond just the technology itself,” said Peter Zaitsev, co-founder at Percona. “It wasn’t simply a matter of companies looking to control costs. It was an expression of widespread dissatisfaction and frustration that people are feeling with self-proclaimed “open source” software vendors suddenly deciding to abandon the model. It was a palpable response, and one we felt here at Percona. That’s why Valkey is the first addition to our list of supported technologies in nearly half a decade. And we will continue to support Valkey, as well as other open source initiatives like it, for as long as they’re here.”</p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">To learn more about Percona Support for Valkey, including our dedicated Valkey Migration and Redis OSS Health Assessments, please visit: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.globenewswire.com/Tracker?data=bJ49Q4vLsWYmTQVMmO0VxK9pr_aR9l-z0jYk58T_9BMskdi7WPLmUoydX7l9DixML4g6p9_GOkUT7VtfQMFyHMpb8MQeczBB-lvoO7_NQSXgtjJpW9E4c4Dk2Sgyw1EbtTBqjQhrGc1aHE7UO2No-EGPG8Qcg8SbXJghlh_g3TM=\" tabindex=\"0\"><span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\">www.percona.com/valkey/support-and-services</span></a></p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">For more information on Valkey, please visit <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.globenewswire.com/Tracker?data=gEgkYQUmy1r0VrALvniTI7nIsMf3Fdk0Guf_LOZkp94a8jehFheFUTagP3I3v1cI7gQisBhaEUmLpbc0Ae-s0Q==\" tabindex=\"0\"><span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\">www.valkey.io</span></a>.</p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About Percona </strong><br data-v-02ca9be7=\"\"/>Percona is a world-class open source database software, support, and services company. The organization is dedicated to helping businesses ensure their databases — and the applications that depend on them — are secure, compliant, performant, and highly available. Through a unique combination of database expertise and enterprise-grade open source software, Percona empowers organizations with the freedom to choose, the freedom to create, and the freedom to innovate with speed as they grow. For more information, visit <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.globenewswire.com/Tracker?data=bJ49Q4vLsWYmTQVMmO0VxEU1F9tcoFLgp5OWrgst76S0LE6deIUKsweNBV-qzDytuHsgTe8a76mi4NlEzjDWIw==\" tabindex=\"0\"><span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\">www.percona.com</span></a>.</p> <p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Media Contact:</strong><br data-v-02ca9be7=\"\"/>Jacob Manchester<br data-v-02ca9be7=\"\"/>Scratch Marketing + Media for Percona<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.globenewswire.com/Tracker?data=RzkYe0uaWXuuMdrTYD8YHfCC-_8H1sepcP7wuynk-qK18mkyRu4TdvOgFdPTwOIiHju4hl0RloU00Y7kCy6bk-yyzd1uPQupVZ0HpFAm7rU=\" tabindex=\"0\"><span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\">jacob@scratchmm.com</span></a><br data-v-02ca9be7=\"\"/>401-636-7757</p> <span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://www.globenewswire.com/newsroom/ti?nf=OTM1MjI3NiM2NzMzNzY2IzUwMDEzMjIxNg== 1x,https://www.globenewswire.com/newsroom/ti?nf=OTM1MjI3NiM2NzMzNzY2IzUwMDEzMjIxNg== 2x,https://www.globenewswire.com/newsroom/ti?nf=OTM1MjI3NiM2NzMzNzY2IzUwMDEzMjIxNg== 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://www.globenewswire.com/newsroom/ti?nf=OTM1MjI3NiM2NzMzNzY2IzUwMDEzMjIxNg== 1x,https://www.globenewswire.com/newsroom/ti?nf=OTM1MjI3NiM2NzMzNzY2IzUwMDEzMjIxNg== 2x,https://www.globenewswire.com/newsroom/ti?nf=OTM1MjI3NiM2NzMzNzY2IzUwMDEzMjIxNg== 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://www.globenewswire.com/newsroom/ti?nf=OTM1MjI3NiM2NzMzNzY2IzUwMDEzMjIxNg== 1x,https://www.globenewswire.com/newsroom/ti?nf=OTM1MjI3NiM2NzMzNzY2IzUwMDEzMjIxNg== 2x,https://www.globenewswire.com/newsroom/ti?nf=OTM1MjI3NiM2NzMzNzY2IzUwMDEzMjIxNg== 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://www.globenewswire.com/newsroom/ti?nf=OTM1MjI3NiM2NzMzNzY2IzUwMDEzMjIxNg==\"/></source></source></source></picture></span> <br/><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://ml.globenewswire.com/media/NzAzNTAwYzktOGYzMC00MjY1LWEzY2MtNWQ0MWY2ODY3MzBiLTUwMDEzMjIxNg==/tiny/Percona.png 1x,https://ml.globenewswire.com/media/NzAzNTAwYzktOGYzMC00MjY1LWEzY2MtNWQ0MWY2ODY3MzBiLTUwMDEzMjIxNg==/tiny/Percona.png 2x,https://ml.globenewswire.com/media/NzAzNTAwYzktOGYzMC00MjY1LWEzY2MtNWQ0MWY2ODY3MzBiLTUwMDEzMjIxNg==/tiny/Percona.png 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://ml.globenewswire.com/media/NzAzNTAwYzktOGYzMC00MjY1LWEzY2MtNWQ0MWY2ODY3MzBiLTUwMDEzMjIxNg==/tiny/Percona.png 1x,https://ml.globenewswire.com/media/NzAzNTAwYzktOGYzMC00MjY1LWEzY2MtNWQ0MWY2ODY3MzBiLTUwMDEzMjIxNg==/tiny/Percona.png 2x,https://ml.globenewswire.com/media/NzAzNTAwYzktOGYzMC00MjY1LWEzY2MtNWQ0MWY2ODY3MzBiLTUwMDEzMjIxNg==/tiny/Percona.png 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://ml.globenewswire.com/media/NzAzNTAwYzktOGYzMC00MjY1LWEzY2MtNWQ0MWY2ODY3MzBiLTUwMDEzMjIxNg==/tiny/Percona.png 1x,https://ml.globenewswire.com/media/NzAzNTAwYzktOGYzMC00MjY1LWEzY2MtNWQ0MWY2ODY3MzBiLTUwMDEzMjIxNg==/tiny/Percona.png 2x,https://ml.globenewswire.com/media/NzAzNTAwYzktOGYzMC00MjY1LWEzY2MtNWQ0MWY2ODY3MzBiLTUwMDEzMjIxNg==/tiny/Percona.png 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://ml.globenewswire.com/media/NzAzNTAwYzktOGYzMC00MjY1LWEzY2MtNWQ0MWY2ODY3MzBiLTUwMDEzMjIxNg==/tiny/Percona.png\"/></source></source></source></picture></span><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.globenewswire.com/NewsRoom/AttachmentNg/f65f2d87-fe29-44aa-be11-bac69e5b6414\" tabindex=\"0\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://ml.globenewswire.com/media/f65f2d87-fe29-44aa-be11-bac69e5b6414/small/percona-horizontal-logo-fullcolor-darktext-png.png 1x,https://ml.globenewswire.com/media/f65f2d87-fe29-44aa-be11-bac69e5b6414/small/percona-horizontal-logo-fullcolor-darktext-png.png 2x,https://ml.globenewswire.com/media/f65f2d87-fe29-44aa-be11-bac69e5b6414/small/percona-horizontal-logo-fullcolor-darktext-png.png 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://ml.globenewswire.com/media/f65f2d87-fe29-44aa-be11-bac69e5b6414/small/percona-horizontal-logo-fullcolor-darktext-png.png 1x,https://ml.globenewswire.com/media/f65f2d87-fe29-44aa-be11-bac69e5b6414/small/percona-horizontal-logo-fullcolor-darktext-png.png 2x,https://ml.globenewswire.com/media/f65f2d87-fe29-44aa-be11-bac69e5b6414/small/percona-horizontal-logo-fullcolor-darktext-png.png 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://ml.globenewswire.com/media/f65f2d87-fe29-44aa-be11-bac69e5b6414/small/percona-horizontal-logo-fullcolor-darktext-png.png 1x,https://ml.globenewswire.com/media/f65f2d87-fe29-44aa-be11-bac69e5b6414/small/percona-horizontal-logo-fullcolor-darktext-png.png 2x,https://ml.globenewswire.com/media/f65f2d87-fe29-44aa-be11-bac69e5b6414/small/percona-horizontal-logo-fullcolor-darktext-png.png 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://ml.globenewswire.com/media/f65f2d87-fe29-44aa-be11-bac69e5b6414/small/percona-horizontal-logo-fullcolor-darktext-png.png\"/></source></source></source></picture></span></a></p></div>",
            "pub_date": "2025-02-04 17:10:53",
            "link": "https://www.morningstar.com/news/globe-newswire/9352276/percona-announces-comprehensive-enterprise-grade-support-for-open-source-redis-alternative-valkey",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Airbus Hires Goldman Sachs to Help Form European Space, Satellite Company, Bloomberg Says, Citing Sources",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  --Airbus has hired Goldman Sachs to assist with forming a new European space-and-satellite company with France's Thales and Italy's Leonardo, to better compete against Elon Musk's SpaceX, Bloomberg reported, citing unnamed sources. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  --Talks to create the business with aerospace company Thales and defense and aerospace group Leonardo are at an exploratory stage, according to the sources, who added that Leonardo has enlisted Bank of America while Thales is also speaking with advisers, the report said. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  --The companies are assessing issues like complexity, regulatory obstacles and possible antitrust implications, Bloomberg reported, citing the sources. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  --Representatives for Airbus, Leonardo, Goldman and BofA declined to comment. Thales reiterated that early discussions have taken place, without commenting on advisers, Bloomberg reported. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Full story: https://shorturl.at/2ZyWb </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Write to Pierre Bertrand at pierre.bertrand@wsj.com </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  February 04, 2025 03:51 ET (08:51 GMT)</p>\n\nCopyright (c) 2025 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2025-02-04 17:00:54",
            "link": "https://www.morningstar.com/news/dow-jones/202502042289/airbus-hires-goldman-sachs-to-help-form-european-space-satellite-company-bloomberg-says-citing-sources",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Tequila has to be made in Mexico. Diageo offers no financial outlook on tariff uncertainty.",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  By Steve Goldstein </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n     The maker of Don Julio tequila and Crown Royal whisky said on Tuesday it can't provide financial guidance because of the uncertainty over tariffs. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n     Diageo, the alcoholic beverage conglomerate, said even with the 30-day delay from the U.S. in imposing 25% tariffs on Canada and Mexico it still can't be sure of what will happen. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n     \"Diageo starts from a position of strength with a broad global portfolio across categories and geographies, and has demonstrated agility in navigating tariffs on input costs in the past. However, in the U.S., our largest market, the products which would be impacted by the tariffs would mainly be our tequila portfolio, which given geographic origin requirements must be made in Mexico, and also Canadian whisky,\" the company said in a statement. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n     Diageo said it's undertaken considerable contingency planning over the last few months, and it said mitigation measures include \"pricing and promotion management, inventory management, supply chain optimization and re-allocation of investments.\" </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n     Diageo shares (UK:DGE) (DEO) dropped 3% in early London trade. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n     Diageo said its fiscal first-half earnings fell 12% to $1.93 billion, as sales fell 1% to $10.9 billion as an unfavorable exchange rate offset a 1% growth in organic sales. The 1.2 percentage point improvement in price and mix was offset by a 0.2% decline in volumes, Diageo said. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n     Don Julio was actually Diageo's top-performing key brand in North America, as organic sales surged 61%. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n     Diageo said U.S. consumers remained under pressure from cyclical macroeconomic factors including inflation, which, despite easing in recent months, remained elevated compared with historic levels. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n     -Steve Goldstein </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  02-04-25 0351ET</p>\n\nCopyright (c) 2025 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2025-02-04 17:00:54",
            "link": "https://www.morningstar.com/news/marketwatch/2025020413/tequila-has-to-be-made-in-mexico-diageo-offers-no-financial-outlook-on-tariff-uncertainty",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "TIXT Investors Have Opportunity to Lead TELUS International (Cda) Inc. Securities Fraud Lawsuit with the Schall Law Firm",
            "description": "<div class=\"mdc-article-body\">\n\n\n\n\n\nTIXT Investors Have Opportunity to Lead TELUS International (Cda) Inc. Securities Fraud Lawsuit with the Schall Law Firm\n\n\n\n\n\n<span>\n<h2 class=\"mdc-article-heading\" data-v-2dc4c42a=\"\">TIXT Investors Have Opportunity to Lead TELUS International (Cda) Inc. Securities Fraud Lawsuit with the Schall Law Firm</h2>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">LOS ANGELES, Feb. 4, 2025</p></span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">LOS ANGELES</span></span>, <span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Feb. 4, 2025</span></span> /PRNewswire/ -- <span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4353603-1&amp;h=2509736450&amp;u=https%3A%2F%2Fschallfirm.com%2F&amp;a=The+Schall+Law+Firm\" tabindex=\"0\">The Schall Law Firm</a></span>, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against TELUS International (Cda) Inc. (\"Telus\" or \"the Company\") (NYSE: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4353603-1&amp;h=607650043&amp;u=https%3A%2F%2Fwww.marketwatch.com%2Finvesting%2Fstock%2FTIXT&amp;a=TIXT\" tabindex=\"0\">TIXT</a>) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule <span data-v-02ca9be7=\"\">10b</span>-5 promulgated thereunder by the U.S. Securities and Exchange Commission.</p>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.html\" tabindex=\"0\">\n<span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg 1x,https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg 2x,https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg 1x,https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg 2x,https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg 1x,https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg 2x,https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg\"/></source></source></source></picture></span>\n</a>\n</p>\n</span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Investors who purchased the Company's securities between February 16, 2023 to <span data-v-02ca9be7=\"\">August 01, 2024</span>, inclusive (the \"Class Period\"), are encouraged to contact the firm before <span data-v-02ca9be7=\"\">March 31</span>, 2025.           </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">If you are a shareholder who suffered a loss, <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4353603-1&amp;h=910014226&amp;u=https%3A%2F%2Fschallfirm.com%2Fcases%2Ftelus-international-cda-inc%2F%23case-form&amp;a=click+here+to+participate\" tabindex=\"0\">click here to participate</a>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">We also encourage you to contact <span data-v-02ca9be7=\"\">Brian Schall</span> of the Schall Law Firm, 2049 Century Park East, Suite 2460, <span data-v-02ca9be7=\"\">Los Angeles, CA</span> 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at <span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4353603-1&amp;h=3213541037&amp;u=http%3A%2F%2Fpr.report%2FmIwBkOrU&amp;a=www.schallfirm.com\" tabindex=\"0\">www.schallfirm.com</a></span>, or by email at <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:bschall@schallfirm.com\" tabindex=\"0\">bschall@schallfirm.com</a>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">According to the Complaint, the Company made false and misleading statements to the market. The AI Data Solutions developed by Telus required the cannibalization of higher-margin offerings. The Company's declining profitability was directly tied to its AI development. The Company's shift to AI placed pressure on its margins. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Telus, investors suffered damages.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4353603-1&amp;h=384223090&amp;u=https%3A%2F%2Fschallfirm.com%2Fcases%2Ftelus-international-cda-inc%2F%23case-form&amp;a=Join+the+case\" tabindex=\"0\">Join the case</a> to recover your losses.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">CONTACT:</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The Schall Law Firm<br data-v-02ca9be7=\"\"/><span data-v-02ca9be7=\"\">Brian Schall, Esq.</span>,<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4353603-1&amp;h=3633761571&amp;u=https%3A%2F%2Fwww.schallfirm.com%2F&amp;a=www.schallfirm.com\" tabindex=\"0\">www.schallfirm.com</a><br data-v-02ca9be7=\"\"/>Office: 310-301-3335<br data-v-02ca9be7=\"\"/><span class=\"mdc-article-underline\" data-v-7ddb3a4c=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:info@schallfirm.com\" tabindex=\"0\">info@schallfirm.com</a></span></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=LA09881&amp;sd=2025-02-03 1x,https://c212.net/c/img/favicon.png?sn=LA09881&amp;sd=2025-02-03 2x,https://c212.net/c/img/favicon.png?sn=LA09881&amp;sd=2025-02-03 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=LA09881&amp;sd=2025-02-03 1x,https://c212.net/c/img/favicon.png?sn=LA09881&amp;sd=2025-02-03 2x,https://c212.net/c/img/favicon.png?sn=LA09881&amp;sd=2025-02-03 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=LA09881&amp;sd=2025-02-03 1x,https://c212.net/c/img/favicon.png?sn=LA09881&amp;sd=2025-02-03 2x,https://c212.net/c/img/favicon.png?sn=LA09881&amp;sd=2025-02-03 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://c212.net/c/img/favicon.png?sn=LA09881&amp;sd=2025-02-03\"/></source></source></source></picture></span> View original content to download multimedia:<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.prnewswire.com/news-releases/tixt-investors-have-opportunity-to-lead-telus-international-cda-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302367225.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/tixt-investors-have-opportunity-to-lead-telus-international-cda-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302367225.html</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SOURCE  The Schall Law Firm</p>\n</span>\n</div>",
            "pub_date": "2025-02-04 16:55:42",
            "link": "https://www.morningstar.com/news/pr-newswire/20250204la09881/tixt-investors-have-opportunity-to-lead-telus-international-cda-inc-securities-fraud-lawsuit-with-the-schall-law-firm",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        }
    ]
}